Pneumococcal

In a meta-analysis conducted between 2013 and 2023, researchers explore the overall impact of interventions geared toward boosting pneumococcal vaccination rates.

Across rural US community pharmacies, researchers explore the common barriers and facilitators to pneumococcal vaccine uptake.

Exploring pneumococcal vaccination rates among eligible adult patients, researchers conducted a quality improvement initiative at a clinic in Illinois.

A new 25-valent pediatric pneumococcal vaccine enters phase 3 after strong data, aiming for broader coverage and improved serotype 3 protection.

Among both childhood and adult populations, researchers assess the quality of life across a large cohort of patients reporting pneumococcal disease cases.

Preventing pneumococcal disease remains a cornerstone of public health, yet the strategy for protection is increasingly individualized and complex.

Researchers explore invasive pneumococcal disease epidemiology after the introduction of multiple pneumococcal conjugate vaccines.

Exploring data across a variety of income settings, researchers conduct a review of invasive pneumococcal disease carriage, cases, and their associations.

In adult patients at least 50 years old, researchers estimated lifetime costs and health outcomes of the 23-valent pneumococcal polysaccharide vaccine.

Low pneumococcal vaccine rates have potential to significantly impact a variety of at-risk populations, even groups of certain health care workers.

New research shows older adults vaccinate more when confident navigating their health care.

Meta-analysis shows PCV13 followed by PPSV23 boosts pneumococcal immunity in seniors without added adverse effects.

Social determinants of health shape pneumococcal risk, making vaccination especially important for specific populations.

In response to evolving serotypes and vaccine guidance, researchers assess the most effective pneumococcal vaccination strategies across Taiwan.

Researchers aim to update and expand on register-based surveillance of severe acute respiratory infections related to Streptococcus pneumoniae in Denmark.

Investigators of the multicenter cohort aim to determine if the 13-valent pneumococcal conjugate vaccine impacted disease activity over a 24-month period.

As population-level introduction of pneumococcal conjugate vaccines has led to an increase in invasive disease, the development of higher-valency vaccines has become a primary solution.

Serotype 19F resurges despite PCVs, raising invasive disease risk in older adults; pharmacists track immune evasion, variants, and boost adherence.

With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden.

CDC researchers investigate pneumococcal disease cases and intervention strategies within a North Carolina correctional facility from June 14 to July 30, 2024.

Researchers investigate PCV25 developments and potential use of the vaccine among adults who are healthy and naïve to the pneumococcal vaccine.

Pneumococcal aortitis is a rare but life-threatening aortic infection that highlights the concerning interplay between pneumococcal disease and cardiovascular disease risk and mortality.

Researchers explore the serotypes, vaccination, and risk factors associated with pneumococcal disease mortality among in-hospital patients in Spain.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

The top pneumococcal stories of 2025 explored the evolving landscape of pneumococcal vaccination.